Boston Scientific Launches Next-Generation LUX-Dx II+ Insertable Cardiac Monitor

Oct 06, 2023 00:02 CST Updated 00:02

Boston Scientific

Medical Device Manufacturer

Source of the article:Heart NotCome;Editor:Huang Chuyan

Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.

Heart Future

October 2, 2023, Boston Scientific (Boston Scientific corporation New York Stock Exchange Code: BSX)Announcing the Launch of the Next-Generation LUX-Dx II+ Insertable Cardiac Monitor (ICM) System.

# Boston Scientific Launches New Generation of Cardiac Monitor

Boston Scientific Corporation today announced the launch of the next-generation LUX-Dx II+ Insertable Cardiac Monitor (ICM) System.The system can monitor for a long term.Arrhythmias associated with AFib, cryptogenic stroke, and syncope.

Insertable cardiac monitors are a highly competitive field. Abbott's Assert-IQ ICM received FDA approval in May, while Medtronic has also released positive data on its Linq monitor.

Boston Scientific Corporation (BostonBoston Scientific) Designed LUX-DxII+ adopts a two-stage algorithm, which can alertClinicians previously detected and validated potential arrhythmias.This provides actionable data for clinical decision-making when clinicians receive the final alert.

LUX-Dx II+ also features remote programming capabilities. This allows physicians and care teams to adjust event detection settings and log symptoms without the need for in-office appointments.

Boston Scientific Corporation stated that the system's two-stage algorithm can identify AFib, atrial and ventricular tachycardia, bradycardia, and rhythm pause monitoring. The algorithm also features a new Premature Ventricular Contraction (PVC) burden function, enabling the device to detect arrhythmias whenever established thresholds or parameters are exceeded.

Additional features of the validation filter can then be applied, including extra options for nighttime programming. Nighttime programming aids in differentiating between actionable detections and irrelevant cardiac events for bradycardia and pause monitoring. Patients can also download an application for more convenient, seamless remote monitoring.

Scott Olson, Senior Vice President of Cardiac Rhythm Management & Diagnostics at Boston Scientific Corporation, stated: "The LUX-Dx II+ ICM system builds on Boston Scientific's strong foundation in cardiac diagnostic technology, providing care teams with the data needed for critical decision-making. With enhanced new diagnostic algorithms, physicians will receive timely, accurate, and actionable insights to help them make clinically meaningful decisions."

# About Boston Scientific

Boston Scientific was founded in 1979, with its headquarters in Natick, Massachusetts, USA. It is a global leading medical technology company. In 1997, Boston Scientific entered China, establishing branch offices and research and development centers in Beijing, Shanghai, and Guangzhou. The company's headquarters in China is located in Shanghai. Boston Scientific has more than 17,000 products and has been granted over 16,000 authorized patents worldwide. In May 1992, Boston Scientific was successfully listed on the New York Stock Exchange. In 2013, Boston Scientific's R&D investment reached 861 million US dollars, making it one of the medical device companies with the highest R&D investment globally.

Overseas Cardiovascular Devices:

Products of Chinese Cardiovascular Companies: